Revona Bio Raises £250K Seed Round for RNA-Targeted Drug Discovery

Revona Bio Adds £250K in Seed Funding

Revona Bio, a female-founded spin-out from the University of Portsmouth, has raised £250,000 in seed funding. The round is dated September 11, 2026. No lead investor was named, and no individual investors were listed in the funding details.

What Revona Bio Does

Revona Bio works on RNA-targeted drug discovery. The company has developed a patented high-throughput RNA biology platform that generates RNA structure and function datasets. Those datasets feed a machine-learning prediction engine.

According to the company, the platform supports:

• Hit identification
• Optimisation of RNA-targeted small molecules
• Safety assessment

The company describes applications across human, animal, and plant health — a notably broad scope for an early-stage platform business.

Company Background

Revona Bio was founded in 2022 as a spin-out from the University of Portsmouth. It is led by co-founders Charlotte Henderson (CEO) and Anastasia Callaghan (CSO). The company is based in the United Kingdom.

Prior to this round, the company had raised around £2.1 million during 2026, according to the available information. This £250,000 seed round adds to that total.

Funding Details at a Glance

• Company: Revona Bio
• Sector: RNA-targeted drug discovery
• Round type: Seed
• Funding amount: £250,000
• Currency: GBP
• Funding date: September 11, 2026
• Lead investor: Not disclosed
• Investors listed: None specified

Why RNA-Targeted Discovery Is a Distinctive Position

RNA-targeted small molecule discovery sits at the intersection of structural biology, high-throughput screening, and machine learning. The core challenge in the field is data: RNA is structurally dynamic, and generating reliable structure-function datasets at scale has historically been difficult. A platform that produces such datasets — and then uses them to train predictive models — addresses a recognized bottleneck in the discovery pipeline.

Revona Bio's patented platform is the central asset described in the company's materials. The combination of wet-lab dataset generation and a machine-learning prediction engine is a model that has attracted increasing attention across the drug discovery sector, though the specific technical claims here are the company's own.

The breadth of stated applications — human, animal, and plant health — suggests a platform play rather than a single-asset therapeutic program. Platform companies at the seed stage typically face a trade-off between demonstrating depth in one area and preserving optionality across several. How Revona Bio prioritizes among these markets is not specified in the available information.

What Remains Unclear

No lead investor was identified, and no investor names were provided. The source URL was not included. As a result, it is not possible to characterize the syndicate behind this round or the specific terms.

The relationship between this £250,000 seed round and the approximately £2.1 million raised during 2026 is also not detailed — whether this is part of a larger financing, a follow-on, or a separate tranche is not stated.

Summary

Revona Bio, a University of Portsmouth spin-out founded in 2022, has raised £250,000 in seed funding dated September 11, 2026. The company operates a patented high-throughput RNA biology platform that generates datasets for a machine-learning prediction engine supporting RNA-targeted small molecule discovery. Co-founders Charlotte Henderson and Anastasia Callaghan lead the company. No lead investor or investor list was disclosed.